Synovac’s Kovid-19 vaccine is 78% effective in Brazilian late-stage trials


China’s Synovac vaccine has shown 78% effective against Kovid-19 in late-stage trials in Brazil and provides total protection against severe cases of the disease, hoping that it will be used for much of the developing world’s vaccination can be done.

Butanon Institute of Brazil, São Paulo-based research center that tested Coronavac in Phase 3 trials, said on Thursday that none of the vaccine volunteers developed serious cases of Kovid-19. More than 12,000 health workers participated in Phase 3 trials in Brazil, the first country to complete Synovac’s vaccine trials.

“This is a fantastic result,” said Luiz Carlos Dias, part of the Kovid-19 task force of researchers at the University of Campinas, São Paulo State. “If it can prevent serious cases, hospitals, deaths, it will help us get out of this epidemic.”

The Coronavac vaccine is less effective, being developed by Modern Inc. and jointly by Pfizer Inc. and BioNtech SE, with efficacy rates of 94.5% and 95%, respectively, in the trial. Infectious disease experts said the Coronavac can be stored in a standard refrigerator between about 36 and 46 degrees Fahrenheit, making it easier and cheaper to transport and store in less transported countries.

Prashant Yadav, a global health expert at the Center for Global Development, a Washington-based think tank, said that for many developing countries, considering using the vaccine is a 78% higher rate and potentially good enough for the World Health Organization to include Consider including Coronavic. Global Distribution System.

.

Leave a Reply

Your email address will not be published.